Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AMPH

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

StockNews.com

3 Small-Cap Healthcare Stocks Wall Street Loves

The healthcare industry is expected to witness robust growth driven by increased demand for medicines. Therefore, small-cap Wall Street healthcare favorites Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and Equillium (EQ) might be ideal additions to your portfolio. Keep reading….

StockNews.com

4 Pharma Stocks to Watch for Surprising Gains in June

Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks to Buy for February Gains

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

StockNews.com

3 Pharma Stocks to Watch in 2024 for Later Gains

The pharmaceutical industry looks well-positioned for long-term growth. Hence, pharma stocks Procaps Group (PROC), Organon (OGN) and Amphastar (AMPH) might be ideal additions to your watchlists for later gains. Read on.

StockNews.com

Will Eli Lilly's Emergency Diabetes Drug Give Amphastar Wings?

AMPH stock has doubled so far this year and is in a buy zone again. It earlier bought Eli Lilly's emergency diabetes drug which can drive future growth.

Investors Business Daily

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this year from Eli Lilly.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade

Amphastar Pharm saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.

Investors Business Daily

Buy These 3 Pharma Stocks in July

The pharmaceutical industry looks well-positioned for long term growth due to the globalization of the industry, increasing investments to develop life-saving drugs, rise in chronic diseases, and a rapidly aging population. To that end, it could be wise to buy fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD),…

StockNews.com

3 Quality Medical Stocks to Explore

The medical industry is envisioned to remain afloat and thrive in the foreseeable future, thanks to advanced medical discoveries. Therefore, quality medical stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD), and Voyager Therapeutics (VYGR) could be wise portfolio additions now. Read on….

StockNews.com

IBD 50 Stock Hits All-Time High, And 44% EPS Growth Expected

This drug stock ranks first out of 790 medical stocks and is in the buy zone. The company plans to roll out its overdose nasal spray in the third quarter.

Investors Business Daily

3 Smart Money Stocks to Invest in Today

Fears of an impending recession have kept the stock market volatile. Therefore, it could be wise to invest in quality stocks APi Group (APG), Amphastar Pharmaceuticals (AMPH), and Aquestive Therapeutics (AQST), which institutional investors hold significantly. Read on….

StockNews.com

Amphastar Pharmaceuticals's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between quarters.

Benzinga

2 Under-the-Radar Pharmaceutical Stocks to Add to Your Watchlist

Irrespective of worsening supply chain disruptions due to the Russia-Ukraine war, the pharmaceutical industry is expected to witness stable growth given the rising medical needs of an aging population and rapid advancements in the drug development process. So, amid an apparent resurgence of COVID-19 cases, we think it could be…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval

The FDA has approved Amphastar Pharmaceuticals Inc's (NASDAQ:AMPH) Abbreviated New Drug Application for Ganirelix Acetate Injection, 250mg/0.5mL in a prefilled syringe. Ganirelix acetate injection is indicated to inhibit premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. The FDA determined Amphastar's ganirelix is bioequivalent and therapeutically equivalent to Organon & Co's (NYSE:OGN) Ganirelix…

Benzinga

Amphastar Pharmaceuticals: Q4 Earnings Insights

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

People

Dipanjan BanchurSince

722 stories

Steve Reitmeister

480 stories

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Medical – Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.